CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
about
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunityDendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytesOral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsHeteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Recent progress in tumour vaccine development.Antigen-specific immunotherapy and cancer vaccines.Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigensNY-ESO-1 immunotherapy for multiple myeloma.Identification of T-cell epitopes for cancer immunotherapy.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Melanoma vaccines: developments over the past 10 years.Colorectal cancer vaccines in clinical trials.Towards in silico design of epitope-based vaccines.Evolving role of tumor antigens for future melanoma therapies.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector.NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue.Neoantigen prediction and the need for validation.DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
P2860
Q24610550-9952ED9E-F228-45C2-9021-013A8C5F03ECQ24806024-E1B190D8-D5BC-4D9B-AF3B-00FC6A8B76CEQ33909195-6EFC441E-FF64-4A4D-9316-50269E448746Q34111719-40DB205C-CCF6-4C4E-B137-DDCEEF28CA6AQ34111757-FE165B43-E25D-40F5-BDA4-53818A1309BCQ34309388-0444F41A-1A28-4DCA-B4EA-B0C5661629B8Q34627677-DFBCCE86-927B-4C96-8488-5813E1AC9623Q34795354-5E9F3628-B320-4BB2-82E7-D965D0158E45Q35039508-4C90C723-25EA-4182-A729-798743953376Q35144001-3113ECCC-9CD2-4909-A406-10D4D3063D7EQ35199473-49565059-B457-47AC-B6F3-BECDDA77B8CAQ35543740-DEF1EFF1-DAEE-4A47-843A-4C7B0CCEBF12Q35921697-F410D3BA-BD9B-4C4E-A797-A171B86DB0E4Q35939427-320E8413-AB05-4548-8B89-6C2C54506731Q36015624-46328A8A-1F6F-419A-9968-6A98628E0BDAQ36471827-B23AE958-5F9F-4F21-B0D0-FD9010601798Q36611909-B32E91CD-5BC0-4E2F-A87E-945FDF98B1E2Q36637651-4A8E4CA7-B855-4C06-82A6-CB55AD5D417EQ36870592-80A6F87B-CEEC-4E39-8AB2-04C5C66D2073Q37762274-58D8A9A0-FE23-43E6-83C0-3B5382C718D5Q37892595-C67B56B3-52F7-48CB-ACA5-B6336975BAD6Q37892600-FAFBE6F2-61C6-4F38-91DC-8D3BA2332352Q38088325-1BD46EAA-5C5C-4C65-BAC4-7F99AF310DB0Q38232855-731AF27D-A638-4F1C-AB80-6F01980C1759Q38445350-8A2E65D5-15E8-4785-B970-C7AEAD1EFA9CQ38693404-19C69D5C-D28B-4094-A827-373EC874E6BAQ39325954-4A3DF072-A61B-43DB-A9C2-EE97AC9E3A4DQ40188864-09E6C07D-6CA8-46B8-844C-CE5503760077Q40598793-96565A58-9BFE-46B0-BC59-FC03D62F8891Q41912576-B9323636-FD05-4DA3-8457-A7A9FEAA94DBQ44264589-414F1CDB-6B5E-4056-B51A-4FC4BB520C31Q44788642-D447CE0E-28DD-42EC-A18A-2EE1492A2DE9Q46969749-E2CBB379-E4AE-4F0D-B5F8-8149AA3E5F2BQ51825111-BB004EDE-0D19-4C41-BBEF-1C3D7AC53E86Q55136811-04B58758-12DC-4CA6-B022-7DBF216FEA01
P2860
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
CD8(+) T cell responses agains ...... munization of cancer patients.
@ast
CD8(+) T cell responses agains ...... munization of cancer patients.
@en
type
label
CD8(+) T cell responses agains ...... munization of cancer patients.
@ast
CD8(+) T cell responses agains ...... munization of cancer patients.
@en
prefLabel
CD8(+) T cell responses agains ...... munization of cancer patients.
@ast
CD8(+) T cell responses agains ...... munization of cancer patients.
@en
P2093
P2860
P356
P1476
CD8(+) T cell responses agains ...... munization of cancer patients.
@en
P2093
Alexander Knuth
Djordje Atanackovic
Elke Jäger
Gerd Ritter
Jonathan Cebon
Lloyd J Old
Mitsutoshi Matsuo
Nasser K Altorki
Qiyuan Chen
Sacha Gnjatic
P2860
P304
11813-11818
P356
10.1073/PNAS.142417699
P407
P577
2002-08-19T00:00:00Z